Supernus v. Aurobindo: 11-Patent Oxcarbazepine Suit Dismissed Without Prejudice
Supernus Pharmaceuticals filed suit against Aurobindo Pharma in the District of New Jersey, asserting 11 patents covering extended-release oxcarbazepine tablets across three dosage strengths. The case closed via stipulated dismissal without prejudice just 77 days after filing — leaving the door open for future enforcement.
11-Patent ANDA Suit Over Oxcarbazepine ER Tablets Closes in 77 Days
On 23 September 2024, Supernus Pharmaceuticals, Inc. filed a patent infringement action against Aurobindo Pharma, Ltd. and its U.S. subsidiary Aurobindo Pharma USA, Inc. in the U.S. District Court for the District of New Jersey. The complaint asserted 11 patents — spanning formulation, composition, and method claims — covering extended-release oxcarbazepine tablets in 150 mg, 300 mg, and 600 mg strengths, consistent with Supernus’s branded Oxtellar XR product line.
The case closed on 9 December 2024, just 77 days after filing, through a Stipulation and Order of Dismissal Without Prejudice. A dismissal without prejudice means neither party obtained a merits ruling: no infringement finding was made, no patent validity was adjudicated, and — critically — Supernus retains the full legal right to refile the same claims against Aurobindo in the future. Aurobindo faces no estoppel from this resolution.
A 77-day resolution in ANDA patent litigation is notably rapid, typically suggesting the parties reached an accommodation — potentially a licensing arrangement or agreed-upon market-entry date — before substantive motion practice began. The public record does not disclose settlement terms, and the stipulated nature of the dismissal prevents inference as to which party, if any, made concessions. The breadth of the patent portfolio asserted — 11 patents across multiple application families — suggests Supernus maintains a layered exclusivity strategy for Oxtellar XR.
Filing to Dismissed without Prejudice in 77 days
77 days — resolved well before ANDA litigation’s typical 30-month stay window
Dismissed without prejudice: what the stipulated order means for both parties
Stipulated dismissal without prejudice ends the case — for now
A dismissal without prejudice via stipulation means both parties agreed to close the case without a court ruling on the merits. No infringement was found; no patent was invalidated. Critically, the ‘without prejudice’ qualifier means Supernus can refile the identical claims against Aurobindo — the case is paused, not resolved. This mechanism is commonly used in ANDA litigation when parties reach a private accommodation they prefer not to disclose publicly.
No merits rulingSupernus retains all enforcement rights across all 11 patents
Supernus emerges from this dismissal with its entire 11-patent portfolio intact and unlitigated. No claim was cancelled, no validity finding constrains future enforcement, and no estoppel attaches. The right to refile against Aurobindo — or any other generic filer — remains fully preserved. This outcome is consistent with a patent holder that achieved its commercial objective (e.g., a negotiated entry date or licence) without needing judicial validation of its IP.
Portfolio fully preservedAurobindo avoids a merits fight but gains no invalidity finding
Aurobindo exits the case without an infringement finding against it, which is commercially significant. However, it also obtained no ruling that any of the 11 asserted patents are invalid or not infringed — meaning Supernus could reassert them if Aurobindo’s ANDA approval or launch plans change. Any agreed market-entry terms, if they exist, are private. Aurobindo’s freedom to launch generic oxcarbazepine ER tablets remains subject to whatever accommodation, if any, was privately negotiated.
No invalidity ruling securedOxtellar XR’s layered patent estate signals continued generic entry barriers
With 11 patents asserted across multiple application families — filing dates spanning 2007 to 2019 — Supernus’s exclusivity strategy for Oxtellar XR appears designed for depth. Other generic manufacturers with pending or contemplated ANDAs for oxcarbazepine ER should treat this dismissal as informative, not permissive: the patent estate remains active and Supernus has demonstrated willingness to litigate. The rapid closure without prejudice also suggests private deal-making is Supernus’s preferred enforcement tool.
Multi-layer exclusivity strategyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | CNS-focused specialty pharma — holder of US9119791B2 and 10 further oxcarbazepine ER patentsSearch in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Indian generic drug manufacturer and its U.S. subsidiary, ANDA filer for oxcarbazepine ER tabletsSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Stipulation and Order of Dismissal Without Prejudice reflects a mutual agreement between Supernus and Aurobindo to close the proceeding without any judicial determination on infringement or patent validity. The phrase ‘without prejudice’ is legally significant: it expressly preserves Supernus’s right to refile identical claims. No claim construction, no summary judgment, and no invalidity ruling was reached. The stipulated form — signed by both parties and entered as a court order — is standard in ANDA settlements and does not imply fault or concession by either side.
US9119791B2 and 10 further patents — oxcarbazepine extended-release formulations
The 11 patents asserted in this action collectively cover extended-release formulations of oxcarbazepine — an anticonvulsant used in epilepsy management — in tablet strengths of 150 mg, 300 mg, and 600 mg, corresponding to Supernus’s Oxtellar XR product. The portfolio spans application filings from 2007 through 2019, encompassing composition-of-matter claims, formulation methods, and therapeutic use claims. This layered structure is characteristic of a mature brand-protection strategy designed to maintain exclusivity across successive patent expiries.
For generic manufacturers, the breadth of this portfolio — 11 patents across at least six distinct application families — creates a complex clearance landscape. A single ANDA Paragraph IV certification triggers litigation risk across all asserted patents simultaneously. The rapid 77-day resolution of this case without any patent being invalidated means every patent in the estate retains its full legal force. CNS-focused generic entrants and any company developing oxcarbazepine ER products should treat this portfolio as an active enforcement asset, not a legacy one.
Should you run an FTO against Supernus’s oxcarbazepine ER patent portfolio?
Any company developing, manufacturing, or seeking ANDA approval for extended-release oxcarbazepine tablets — in any dosage strength — faces direct exposure to the 11 patents asserted in this case. This matters not only for Paragraph IV ANDA filers but also for 505(b)(2) applicants and any branded reformulation developer working in the oxcarbazepine space. Given that none of these patents were invalidated in this proceeding, the freedom-to-operate question remains fully open and commercially critical.
PatSnap Eureka’s FTO Search Agent can map each of the 11 asserted patents against your product claims, identify expiry dates and prosecution history, flag continuation risk, and surface prior art that may support invalidity arguments. For a portfolio this size, automated claim-charting and family-level analysis dramatically reduces the time and cost of manual FTO. Start with US9119791B2 as the anchor patent and expand across the full application family tree.
Run a freedom-to-operate analysis on US9119791B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: oxcarbazepine and CNS extended-release formulations
Explore comparable ANDA infringement actions in the District of New Jersey involving extended-release CNS drug formulations and multi-patent brand-protection strategies.
What this case signals for the oxcarbazepine ER and CNS drug IP landscape
A 77-day ANDA suit closed by stipulation across 11 patents reveals how branded CNS companies manage generic entry threats.
11-patent portfolios in ANDA litigation are a structural deterrent
Asserting 11 patents simultaneously raises the cost and complexity of generic defense substantially. Even if some patents are vulnerable, challengers must litigate each. Supernus’s strategy — filing broadly and settling quickly — suggests the volume itself was a negotiating tool, not just a litigation tactic.
Dismissal without prejudice should not be read as generic clearance
Other Aurobindo competitors or market-watchers should not interpret this dismissal as a green light for generic oxcarbazepine ER entry. None of the 11 patents were invalidated or found non-infringed. The D.N.J. docket reflects a private resolution, not a public patent clearance event.
Supernus v Aurobindo — key questions answered
A dismissal without prejudice means the court made no ruling on infringement or patent validity. Supernus retains the full legal right to refile the same 11 patent claims against Aurobindo in the future. Aurobindo gains no invalidity finding or estoppel protection from this resolution. The case closed by mutual stipulation — both parties agreed to end the proceeding on these terms.
Supernus asserted 11 patents: US9119791B2, US11166960B2, US9855278B2, US11896599B2, US8617600B2, US7722898B2, US9351975B2, US10220042B2, US9370525B2, US8821930B2, and US7910131B2. All relate to extended-release oxcarbazepine formulations in 150 mg, 300 mg, and 600 mg tablet strengths, consistent with the Oxtellar XR product line.
A 77-day resolution in ANDA patent litigation is unusually fast and typically suggests a private commercial accommodation was reached — such as a negotiated market-entry date or licensing agreement — before substantive motion practice began. The public record does not disclose terms, and the stipulated dismissal form neither confirms nor denies a settlement. The 30-month ANDA stay mechanism means Supernus’s filing itself triggers a period of automatic generic delay.
No. A dismissal without prejudice does not invalidate any patent or find non-infringement. None of Supernus’s 11 asserted patents were adjudicated on the merits. Other generic manufacturers with pending ANDAs for oxcarbazepine ER tablets remain subject to the same patent estate. The dismissal reflects a private resolution between Supernus and Aurobindo only and has no precedential or preclusive effect on third-party generic filers.
The case was filed in the U.S. District Court for the District of New Jersey (Case No. 1:24-cv-09380). The District of New Jersey is the primary venue for ANDA patent litigation in the United States, given the concentration of pharmaceutical companies in the region. Supernus was represented by Saul Ewing LLP. No defendant counsel is recorded in the public docket for this proceeding.
PatSnap Eureka searches patents and litigation data to answer instantly.